April 03, 2020
Voyager Therapeutics Provides Update On The RESTORE-1 Parkinson’s Disease Trial
April 02, 2020
GBT
GBT Commits $250,000 to Support the Sickle Cell Disease Community During COVID-19 Pandemic
April 02, 2020
Fulcrum Therapeutics
Fulcrum Therapeutics Provides Business Update on Impact of COVID-19
April 01, 2020
Blueprint Medicines
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
March 31, 2020
bluebird bio
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA